Bio-Rad Laboratories, Inc. (BIO) Expected to Post Quarterly Sales of $617.23 Million
Analysts expect Bio-Rad Laboratories, Inc. (NYSE:BIO) to post sales of $617.23 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Bio-Rad Laboratories’ earnings, with estimates ranging from $613.68 million to $620.00 million. Bio-Rad Laboratories reported sales of $571.45 million in the same quarter last year, which indicates a positive year-over-year growth rate of 8%. The company is scheduled to report its next quarterly earnings report on Thursday, February 22nd.
According to Zacks, analysts expect that Bio-Rad Laboratories will report full-year sales of $617.23 million for the current year, with estimates ranging from $2.15 billion to $2.16 billion. For the next year, analysts expect that the business will post sales of $2.26 billion per share, with estimates ranging from $2.24 billion to $2.27 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Bio-Rad Laboratories.
Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.54 by $0.37. The business had revenue of $535.00 million during the quarter, compared to analyst estimates of $507.99 million. Bio-Rad Laboratories had a return on equity of 3.44% and a net margin of 1.15%. Bio-Rad Laboratories’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.62 EPS.
Bio-Rad Laboratories (NYSE:BIO) traded up $0.74 during midday trading on Tuesday, reaching $249.11. The company had a trading volume of 106,089 shares, compared to its average volume of 171,580. The stock has a market cap of $7,392.24, a price-to-earnings ratio of 315.33, a P/E/G ratio of 2.01 and a beta of 0.97. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.06 and a quick ratio of 2.77. Bio-Rad Laboratories has a twelve month low of $183.43 and a twelve month high of $273.87.
Bio-Rad Laboratories declared that its Board of Directors has initiated a share repurchase plan on Tuesday, November 28th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the medical research company to buy shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.
In other news, CFO Christine A. Tsingos sold 4,980 shares of the stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $249.40, for a total transaction of $1,242,012.00. Following the completion of the transaction, the chief financial officer now owns 7,283 shares in the company, valued at approximately $1,816,380.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael Crowley sold 1,000 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $258.39, for a total value of $258,390.00. Following the transaction, the executive vice president now owns 2,492 shares of the company’s stock, valued at approximately $643,907.88. The disclosure for this sale can be found here. Insiders sold a total of 9,126 shares of company stock valued at $2,309,426 in the last 90 days. Corporate insiders own 28.29% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Pacad Investment Ltd. bought a new position in shares of Bio-Rad Laboratories during the 2nd quarter worth $113,000. First Manhattan Co. grew its stake in shares of Bio-Rad Laboratories by 71.6% during the 3rd quarter. First Manhattan Co. now owns 599 shares of the medical research company’s stock worth $133,000 after acquiring an additional 250 shares during the period. Meeder Asset Management Inc. grew its stake in shares of Bio-Rad Laboratories by 3,333.3% during the 3rd quarter. Meeder Asset Management Inc. now owns 618 shares of the medical research company’s stock worth $137,000 after acquiring an additional 600 shares during the period. Advisor Group Inc. grew its stake in shares of Bio-Rad Laboratories by 17.8% during the 2nd quarter. Advisor Group Inc. now owns 952 shares of the medical research company’s stock worth $216,000 after acquiring an additional 144 shares during the period. Finally, Timber Hill LLC bought a new position in shares of Bio-Rad Laboratories during the 3rd quarter worth $214,000. Institutional investors own 63.88% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/16/bio-rad-laboratories-inc-bio-expected-to-post-quarterly-sales-of-617-23-million.html.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.